Skip to search formSkip to main contentSkip to account menu

ribociclib

Known as: 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide 
An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

AminopyridinesPurines

Narrower (1)

LEE011
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
1016 Background: The combination of CDK4/6 inhibitor (CDK4/6i) + endocrine therapy (ET) provides consistent improvement in PFS… 
Review
2019
Review
2019
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis.
2019
2019
BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Review
2018
Review
2018
Assessing the possibilities of designing a unified multistep continuous flow synthesis platform
The multistep flow synthesis of complex molecules has gained momentum over the last few years. A wide range of reaction types and… 
2018
2018
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2− advanced or metastatic breast cancer
Abstract Objectives: The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor… 
Review
2017
Review
2017
Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer
ABSTRACT Introduction: The introduction of CDK4/6 inhibitors, such as ribociclib, has changed the treatment landscape for post… 
2016
2016
Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.
568Background: Ribociclib (cyclin dependent kinase 4/6 inhibitor; LEE) acts synergistically with letrozole (LET) in preclinical… 
2016
2016
Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer
Background: Everolimus (EVE; 10 mg) and exemestane (EXE; 25 mg) doublet therapy improved progression-free survival in women with… 
2015
2015
Successful implementation of a novel trial model: The Signature program.
106 Background: Here we describe 8 ongoing single agent clinical protocols under Novartis’ “Signature” program involving… 
1978
1978
Sarcoma of soft tissue
IRB# 16070 A Phase 1B Study of Ribociclib in Combination with Doxorubicin in Advanced Soft Tissue Sarcomas No Trials Currently… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)